Patent application number | Description | Published |
20080199427 | Novel pyridazine compound and use thereof - A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections | 08-21-2008 |
20090036460 | Crystalline pyridazine compound - A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections | 02-05-2009 |
20100028301 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT - The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general Formula (A) wherein the substituents are described in the specification. The invention also relates to processes for the preparation and screening of compounds according to the invention having above mentioned general Formula and their use in the treatment or prophylaxis of viral infections. | 02-04-2010 |
20100063059 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF - A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided. | 03-11-2010 |
20100152444 | NOVEL PYRIDAZINE COMPOUND AND USE THEREOF - A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections | 06-17-2010 |
20120108601 | CRYSTALLINE PYRIDAZINE COMPOUND - A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections | 05-03-2012 |
20130136776 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS - Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period. | 05-30-2013 |
20140212487 | SOLID DISPERSION FORMULATION OF AN ANTIVIRAL COMPOUND - Disclosed are solid dispersions comprising ledipasvir, wherein ledipasvir is dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer, and further wherein ledipasvir is substantially amorphous. Also disclosed are pharmaceutical compositions comprising solid dispersion and methods of using the solid dispersion. | 07-31-2014 |
20140212491 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir. | 07-31-2014 |
20150064252 | SOLID DISPERSION FORMULATION OF AN ANTIVIRAL COMPOUND - Disclosed are solid dispersions comprising a compound having the formula: | 03-05-2015 |
20150064253 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Disclosed are pharmaceutical compositions comprising Compound I, having the formula: | 03-05-2015 |